FI105012B - Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi - Google Patents

Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi Download PDF

Info

Publication number
FI105012B
FI105012B FI923402A FI923402A FI105012B FI 105012 B FI105012 B FI 105012B FI 923402 A FI923402 A FI 923402A FI 923402 A FI923402 A FI 923402A FI 105012 B FI105012 B FI 105012B
Authority
FI
Finland
Prior art keywords
cyclodextrin
erythropoietin
epo
aqueous solution
hydroxypropyl
Prior art date
Application number
FI923402A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI923402A (fi
FI923402A0 (fi
Inventor
Jean Louis Mesens
Frank Jozefy Konings
Marcus Joannes Maria Noppe
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10670074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI105012(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI923402A publication Critical patent/FI923402A/fi
Publication of FI923402A0 publication Critical patent/FI923402A0/fi
Application granted granted Critical
Publication of FI105012B publication Critical patent/FI105012B/fi

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Peptides Or Proteins (AREA)
FI923402A 1990-01-29 1992-07-28 Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi FI105012B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909001987A GB9001987D0 (en) 1990-01-29 1990-01-29 Improved cyclodextrin based erythropietin formulation
GB9001987 1990-01-29
PCT/EP1991/000173 WO1991011200A1 (en) 1990-01-29 1991-01-25 Improved cyclodextrin based erythropoietin formulation
EP9100173 1991-01-25

Publications (3)

Publication Number Publication Date
FI923402A FI923402A (fi) 1992-07-28
FI923402A0 FI923402A0 (fi) 1992-07-28
FI105012B true FI105012B (fi) 2000-05-31

Family

ID=10670074

Family Applications (1)

Application Number Title Priority Date Filing Date
FI923402A FI105012B (fi) 1990-01-29 1992-07-28 Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi

Country Status (20)

Country Link
US (1) US5376632A (ja)
EP (1) EP0513072B1 (ja)
JP (1) JP2997052B2 (ja)
KR (1) KR0183445B1 (ja)
AT (1) ATE107518T1 (ja)
AU (1) AU648061B2 (ja)
CA (1) CA2074820C (ja)
DE (1) DE69102627T2 (ja)
DK (1) DK0513072T3 (ja)
ES (1) ES2059115T3 (ja)
FI (1) FI105012B (ja)
GB (1) GB9001987D0 (ja)
HU (1) HU218213B (ja)
IE (1) IE65209B1 (ja)
IL (1) IL97019A (ja)
NO (1) NO304728B1 (ja)
NZ (1) NZ236938A (ja)
PT (1) PT96593B (ja)
WO (1) WO1991011200A1 (ja)
ZA (1) ZA91620B (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
JP2000509374A (ja) 1996-04-19 2000-07-25 アルファ セラピュティック コーポレイション 凍結乾燥した血液タンパク質のウイルス不活性化方法
US5754937A (en) 1996-05-15 1998-05-19 Stackpole Limited Hi-density forming process
DK0977582T3 (da) * 1997-03-18 2002-12-16 Roche Diagnostics Gmbh Farmaceutiske kombinationspræparater, der indeholder erythropoietin og jernpræparater
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
JP2002523475A (ja) 1998-09-02 2002-07-30 アラーガン・セイルズ・インコーポレイテッド 防腐したシクロデキストリン含有組成物
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
ATE401908T1 (de) * 1999-04-09 2008-08-15 Ortho Mcneil Pharm Inc Pharmazeutische zusammensetzungen von erythropoietin
US20040038878A1 (en) * 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
US20060235366A1 (en) * 2000-12-20 2006-10-19 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
JPWO2003006052A1 (ja) * 2001-07-09 2005-02-17 山之内製薬株式会社 徐放性注射剤用組成物およびその製造方法
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
KR100610003B1 (ko) 2003-06-10 2006-08-08 주식회사 엘지생명과학 혈청 알부민을 함유하지 않는 안정한 인 에리쓰로포이에틴용액 제형
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20110236902A1 (en) * 2004-12-13 2011-09-29 Tyco Healthcare Group Lp Testing a patient population having a cardiovascular condition for drug efficacy
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
BRPI0717460A2 (pt) 2006-10-20 2013-12-24 Icos Corp Composições de inibidores de chk1
DK2590666T3 (en) * 2010-07-06 2017-07-17 Augustinus Bader TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4920214A (en) * 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers

Also Published As

Publication number Publication date
HU9202432D0 (en) 1992-10-28
HUT62198A (en) 1993-04-28
NO304728B1 (no) 1999-02-08
DE69102627D1 (de) 1994-07-28
FI923402A (fi) 1992-07-28
IE910286A1 (en) 1991-07-31
NO922990D0 (no) 1992-07-29
NO922990L (no) 1992-07-29
JP2997052B2 (ja) 2000-01-11
PT96593A (pt) 1991-10-15
US5376632A (en) 1994-12-27
NZ236938A (en) 1992-07-28
EP0513072B1 (en) 1994-06-22
IL97019A (en) 1997-07-13
IL97019A0 (en) 1992-03-29
CA2074820C (en) 2003-10-14
AU648061B2 (en) 1994-04-14
DK0513072T3 (da) 1994-08-01
GB9001987D0 (en) 1990-03-28
ES2059115T3 (es) 1994-11-01
HU218213B (hu) 2000-06-28
EP0513072A1 (en) 1992-11-19
JPH05503700A (ja) 1993-06-17
KR0183445B1 (en) 1999-05-01
ZA91620B (en) 1992-10-28
WO1991011200A1 (en) 1991-08-08
CA2074820A1 (en) 1991-07-30
ATE107518T1 (de) 1994-07-15
PT96593B (pt) 2001-06-29
IE65209B1 (en) 1995-10-04
AU7149791A (en) 1991-08-21
DE69102627T2 (de) 1994-11-03
FI923402A0 (fi) 1992-07-28

Similar Documents

Publication Publication Date Title
FI105012B (fi) Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi
Brewster et al. Use of 2-hydroxypropyl-β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs
Irie et al. Hydroxypropylcyclodextrins in parenteral use. I: Lipid dissolution and effects on lipid transfers in vitro
JP6444548B2 (ja) スルホアルキルエーテルシクロデキストリン組成物
US10323103B2 (en) Alkylated cyclodextrin compositions and processes for preparing and using the same
EP1501496B1 (en) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20030055023A1 (en) Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
RU2322254C2 (ru) Жидкий препарат, содержащий олигопептиды и этерифицированный циклодекстрин
JP2015535014A (ja) アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
JPH07316065A (ja) Ｆｒ９０１４６９物質製剤
US20230357451A1 (en) Alkylated cyclodextrin compositions and processes for preparing and using the same
JPH0129482B2 (ja)
JPS6131121B2 (ja)

Legal Events

Date Code Title Description
MA Patent expired